5o4e - Revision history

OCA at 07:22, 17 October 2024

2024-10-17T07:22:17Z

← Older revision		Revision as of 07:22, 17 October 2024
Line 19:		Line 19:
	</div>		</div>
	<div class="pdbe-citations 5o4e" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5o4e" style="background-color:#fffaf0;"></div>

			==See Also==
			*[[VEGF 3D Structures\|VEGF 3D Structures]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 19:07, 29 November 2023

2023-11-29T19:07:55Z

← Older revision		Revision as of 19:07, 29 November 2023
Line 3:		Line 3:
	<StructureSection load='5o4e' size='340' side='right'caption='[[5o4e]], [[Resolution\|resolution]] 2.15Å' scene=''>		<StructureSection load='5o4e' size='340' side='right'caption='[[5o4e]], [[Resolution\|resolution]] 2.15Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5o4e]] is a 6 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O4E OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5O4E FirstGlance]. <br>		<table><tr><td colspan='2'>[[5o4e]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O4E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5O4E FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CAC:CACODYLATE+ION'>CAC</scene>, <scene name='pdbligand=~~MPD~~:~~(4S)~~-2-~~METHYL-2,4-PENTANEDIOL~~'>~~MPD~~</scene>, <scene name='pdbligand=~~MRD~~:~~(4R)~~-2-~~METHYLPENTANE-2,4-DIOL~~'>~~MRD~~</scene>, <scene name='pdbligand=~~TRS~~:2-~~AMINO~~-2~~-HYDROXYMETHYL-PROPANE-1~~,3-~~DIOL~~'>~~TRS~~</scene>, <scene name='pdbligand=~~FUC~~:~~ALPHA~~-L-~~FUCOSE'>FUC</scene>~~, ~~<scene name='pdbligand=MAN:ALPHA~~-~~D-MANNOSE~~'>~~MAN~~</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene><~~/td></tr>~~		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.15Å</td></tr>
	~~<tr id~~='~~related'><td class~~=~~"sblockLbl"><b>[[Related_structure\|Related~~:~~]]</b></td><td class="sblockDat">[[5k64\|5k64]]~~, ~~[[5k65\|5k65]]</td></tr>~~		<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CAC:CACODYLATE+ION'>CAC</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=MPD:(4S)-2-METHYL-2,4-PENTANEDIOL'>MPD</scene>, <scene name='pdbligand=MRD:(4R)-2-METHYLPENTANE-2,4-DIOL'>MRD</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr>
	~~<tr id='gene~~'>~~<td class="sblockLbl"><b>[[Gene\|Gene:]]~~</~~b></td><td class="sblockDat"~~>~~VEGFA, VEGF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5o4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o4e OCA], [https://pdbe.org/5o4e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5o4e RCSB], [https://www.ebi.ac.uk/pdbsum/5o4e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5o4e ProSAT]</span></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5o4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o4e OCA], [~~http~~://pdbe.org/5o4e PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5o4e RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5o4e PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5o4e ProSAT]</span></td></tr>
	</table>		</table>
	~~== Disease ==~~
	[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[http://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref> [[http://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN]] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref>		[https://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 19:
	</div>		</div>
	<div class="pdbe-citations 5o4e" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5o4e" style="background-color:#fffaf0;"></div>

	~~==See Also==~~
	*[[VEGF 3D Structures\|VEGF 3D Structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Human~~]]		[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
	[[Category: Djinovic-Carugo, K]]		[[Category: Djinovic-Carugo K]]
	[[Category: Humm, A]]		[[Category: Humm A]]
	[[Category: Kubinger, K]]		[[Category: Kubinger K]]
	[[Category: Lobner, E]]		[[Category: Lobner E]]
	[[Category: Mlynek, G]]		[[Category: Mlynek G]]
	[[Category: Obinger, C]]		[[Category: Obinger C]]
	~~[[Category: Antibody engineering]]~~
	~~[[Category: Ch3 domain]]~~
	~~[[Category: Fc fragment]]~~
	~~[[Category: Fcab]]~~
	~~[[Category: Heterodimeric fcab]]~~
	~~[[Category: Immune system]]~~
	~~[[Category: Immunoglobulin g1]]~~
	~~[[Category: Vascular endothelial growth factor]]~~
	~~[[Category: Vegf~~]]

OCA at 12:17, 26 August 2020

2020-08-26T12:17:39Z

← Older revision		Revision as of 12:17, 26 August 2020
Line 1:		Line 1:

	==Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6==		==Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6==
	<StructureSection load='5o4e' size='340' side='right' caption='[[5o4e]], [[Resolution\|resolution]] 2.15Å' scene=''>		<StructureSection load='5o4e' size='340' side='right'caption='[[5o4e]], [[Resolution\|resolution]] 2.15Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[5o4e]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O4E OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca.weizmann.ac~~.~~il/oca-docs~~/fgij/fg.htm?mol=5O4E FirstGlance]. <br>		<table><tr><td colspan='2'>[[5o4e]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O4E OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5O4E FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CAC:CACODYLATE+ION'>CAC</scene>, <scene name='pdbligand=~~FUC~~:~~ALPHA~~-L-~~FUCOSE~~'>~~FUC~~</scene>, <scene name='pdbligand=~~MAN~~:~~ALPHA~~-D-~~MANNOSE~~'>~~MAN~~</scene>, <scene name='pdbligand=~~MPD~~:~~(4S)~~-2-~~METHYL~~-2,4-~~PENTANEDIOL~~'>~~MPD~~</scene>, <scene name='pdbligand=~~MRD~~:~~(4R)~~-2-~~METHYLPENTANE-2,4-DIOL~~'>~~MRD~~</scene>, <scene name='pdbligand=~~NAG~~:~~N-ACETYL~~-D-~~GLUCOSAMINE~~'>~~NAG~~</scene>, <scene name='pdbligand=~~TRS~~:2-~~AMINO~~-2-~~HYDROXYMETHYL-PROPANE-1,3-DIOL~~'>~~TRS~~</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CAC:CACODYLATE+ION'>CAC</scene>, <scene name='pdbligand=MPD:(4S)-2-METHYL-2,4-PENTANEDIOL'>MPD</scene>, <scene name='pdbligand=MRD:(4R)-2-METHYLPENTANE-2,4-DIOL'>MRD</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5k64\|5k64]], [[5k65\|5k65]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5k64\|5k64]], [[5k65\|5k65]]</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5o4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o4e OCA], [http://pdbe.org/5o4e PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5o4e RCSB], [http://www.ebi.ac.uk/pdbsum/5o4e PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5o4e ProSAT]</span></td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">VEGFA, VEGF ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
			<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5o4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o4e OCA], [http://pdbe.org/5o4e PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5o4e RCSB], [http://www.ebi.ac.uk/pdbsum/5o4e PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5o4e ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 21:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 5o4e" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5o4e" style="background-color:#fffaf0;"></div>

			==See Also==
			*[[VEGF 3D Structures\|VEGF 3D Structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
			[[Category: Human]]
			[[Category: Large Structures]]
	[[Category: Djinovic-Carugo, K]]		[[Category: Djinovic-Carugo, K]]
	[[Category: Humm, A]]		[[Category: Humm, A]]

OCA: Protected "5o4e" [edit=sysop:move=sysop]

2017-08-30T04:08:55Z

Protected "5o4e" [edit=sysop:move=sysop]

← Older revision	Revision as of 04:08, 30 August 2017
(No difference)

OCA: New page: ==Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6==
2017-08-30T04:08:53Z

New page: ==Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6== <StructureSection load='5o4e' size='340' side='right' caption='5o4e, resolution 2.15Å' s...

New page

==Crystal structure of VEGF in complex with heterodimeric Fcab JanusCT6==
<StructureSection load='5o4e' size='340' side='right' caption='[[5o4e]], [[Resolution|resolution]] 2.15Å' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[5o4e]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5O4E OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5O4E FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=CAC:CACODYLATE+ION'>CAC</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=MPD:(4S)-2-METHYL-2,4-PENTANEDIOL'>MPD</scene>, <scene name='pdbligand=MRD:(4R)-2-METHYLPENTANE-2,4-DIOL'>MRD</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=TRS:2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL'>TRS</scene></td></tr>
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5k64|5k64]], [[5k65|5k65]]</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5o4e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5o4e OCA], [http://pdbe.org/5o4e PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5o4e RCSB], [http://www.ebi.ac.uk/pdbsum/5o4e PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5o4e ProSAT]</span></td></tr>
</table>
== Disease ==
[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1) [MIM:[http://omim.org/entry/603933 603933]]. These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.
== Function ==
[[http://www.uniprot.org/uniprot/VEGFA_HUMAN VEGFA_HUMAN]] Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth.<ref>PMID:11427521</ref> <ref>PMID:15520188</ref> <ref>PMID:16489009</ref> [[http://www.uniprot.org/uniprot/IGG1_HUMAN IGG1_HUMAN]] Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170).<ref>PMID:17576170</ref> <ref>PMID:20176268</ref> <ref>PMID:22158414</ref>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Fcabs (Fc domain with antigen-binding sites) are promising novel therapeutics. By engineering of the C-terminal loops of the CH3 domains, two antigen binding sites can be inserted in close proximity. In order to elucidate the binding mode(s) between homodimeric Fcabs and small homodimeric antigens, the interaction between the Fcabs 448 and CT6 (having the AB, CD and EF loops and the C-termini engineered) with homodimeric VEGF was investigated. The crystal structures of these Fcabs, which form polymers with the antigen VEGF in solution, were determined. However, construction of heterodimeric Fcabs (JanusFcabs: one chain Fc-wt, one chain VEGF-binding) results in formation of distinct JanusFcab-VEGF complexes (2:1), which allowed elucidation of the crystal structure of the JanusCT6-VEGF complex at 2.15 A resolution. VEGF binding to Janus448 and JanusCT6 is shown to be entropically unfavorable, but enthalpically favorable. Structure-function relationships are discussed with respect to Fcab design and engineering strategies.

Two-Faced Fcab Prevents Polymerization with VEGF and Reveals Thermodynamics and the 2.15 A Crystal Structure of the Complex.,Lobner E, Humm AS, Mlynek G, Kubinger K, Kitzmuller M, Traxlmayr MW, Djinovic-Carugo K, Obinger C MAbs. 2017 Aug 17:0. doi: 10.1080/19420862.2017.1364825. PMID:28816592<ref>PMID:28816592</ref>

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 5o4e" style="background-color:#fffaf0;"></div>
== References ==
<references/>
TOC
</StructureSection>
[[Category: Djinovic-Carugo, K]]
[[Category: Humm, A]]
[[Category: Kubinger, K]]
[[Category: Lobner, E]]
[[Category: Mlynek, G]]
[[Category: Obinger, C]]
[[Category: Antibody engineering]]
[[Category: Ch3 domain]]
[[Category: Fc fragment]]
[[Category: Fcab]]
[[Category: Heterodimeric fcab]]
[[Category: Immune system]]
[[Category: Immunoglobulin g1]]
[[Category: Vascular endothelial growth factor]]
[[Category: Vegf]]